share_log

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Benzinga ·  Jun 14 19:15

The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Aclaris Therapeutics

  • The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 1,611,200 shares at an average price of $1.11. To acquire these shares, it cost around $1.78 million.
  • What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
  • What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.

Zomedica

  • The Trade: Zomedica Corp. (NYSE:ZOM) Vice President of Sales Russell Kevin Klass acquired a total of 299,993 shares at an average price of $0.16. To acquire these shares, it cost around $46,529.
  • What's Happening: On May 15, Zomedica announced the launch of Over-the-Air software and firmware update capability for its TRUFORMA point-of-care diagnostic platform.
  • What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

Perspective Therapeutics

  • The Trade: Perspective Therapeutics, Inc. (NASDAQ:CATX) CEO Johan M. Spoor acquired a total of 100,000 at an average price of $1.17. The insider spent around $117,430 to buy those shares.
  • What's Happening: On June 11, Perspective Therapeutics announced a 1-for-10 reverse stock split.
  • What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.

Now Read This: Top 3 Tech Stocks That May Fall Off A Cliff This Month

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment